Table 1.
Paper | Doses () | Exposure window | Exposure route | Strain, species | Outcomes |
---|---|---|---|---|---|
(Cabaton et al. 2013) | 0.025, 0.25, 25 | GD8–PND16 | Osmotic pump | CD-1 mice | Disrupted global metabolism () PND2, 21; significant doses: 0.025, 0.25, |
1, 10 | Perinatal | Water | S-D rats | Increased BW and visceral adipose tissue, abnormal lipid levels, lower adiponectin levels; significant doses: 1 and | |
(García-Arevalo et al. 2014) | 10 | GD9–GD16 | Subcutaneous | OF-1 mice | Increased BW and increased weight of fat pad mass increased hepatic triglyceride levels, alterations of mRNA gene expression of genes involved in lipogenesis and liver metabolism () PND196; significant dose: |
(Kabuto et al. 2004) | 5, 10 () | Embryonic/fetal and throughout lactation | Water | ICR mice | No effect on BW () |
(Miyawaki et al. 2007)a | 1, 10 () | GD10–throughout lactation | Water | ICR mice | Increased BW (, ) adipose tissue weight, total cholesterol levels () and triacylglycerol levels () PND31; significant doses: 1 and |
(Newbold et al. 2007a) | 10, 100, 1,000 | Perinatal | Subcutaneous | CD-1 mice | No effect on BW () |
(Roepke et al. 2016) | 50, 5,000 | Embryonic day 18–21 and PND0–PND7 | i.p to dams, subcutaneous to pups | FCDC rats | No effect on BW, decreased levels of adipoR1, no change in ER1, 2 or levels () PND50–60; significant doses: 50 and |
(Rubin et al. 2016) | 0.25, 2.5, 25, 250 | Perinatal (P) or perinatal and peripubertally () | Osmotic pump | CD-1 mice | Increased BW (P and ) PND28 and 35; elevated insulin levels (P and ) PND196 and 238; and elevated glucose levels () PND238; significant doses: 0.25 and |
(Ryan and Vandenbergh 2006) | 2, 200 | GD3-PND21 | Gavage | C57/Bl-6 mice | No effect on BW (, ) |
(Ryan et al. 2010) | 0.25 | GD1–PND21 | Diet | CD-1 mice | Increased BW and length that did not persist throughout adulthood (, ) PND21; significant dose: |
(Somm et al. 2009) | 70 | GD6–PND21 | Water | S-D rats | Increased BW PND1 (, ), PND21 (); increased pWAT and BAT mass, adipocyte hypertrophy and alterations of mRNA gene expression of genes involved in metabolism and lipogenesis PND21(); significant dose: |
(Susiarjo et al. 2015) | 10, 10,000 | Perinatal | Diet | C57BL/6 mice | Decreased BW PND1; increased BW, higher body fat content, and impaired glucose homeostasis () PND98–117; significant dose: |
(Tremblay-Franco et al. 2015) | 0.25, 2.5, 25, 250 | Perinatal | Osmotic pump | S-D rats | Metabolic changes in liver and serum composition (, ) PND21, 50, 90, 140 and 200; significant doses: 0.25, 2.5, 25, and |
(van Esterik et al. 2014)b | 3, 10, 30, 100, 300, 1,000, 3,000 | Gestation and lactation | Diet | Hybrid C57BL/6J mice | Increased () and decreased () BW, decreased fat pad weights, adipocyte size (increased in , not dose-dependent), and levels of serum triglycerides, leptin, and adiponectin () PND147 (effects were dose-dependent) |
(Wei et al. 2011) | 50, 250, 1,250 | GD0–PND21 | Oral gavage | Wistar rats | Increased body fat percentage (, ), increased levels of triglycerides and size of adipocytes () PND189; significant dose: |
This study | 0.5, 50 | GD3.5–PND22 | Water | F344 rats | No effect on BW. Increased plasma triglycerides, adipocyte density (decreased adipocyte size), and alterations of mRNA expression of genes involved in lipogenesis, adipocyte adiponectin signaling, and liver metabolism (e.g, increased levels of adipoR1, no change in ER1, 2, or levels) (, ) PND22; significant doses: 0.5 and |
Note: Adipor1, adiponectin receptor 1; BAT, brown adipose tissue; BW, body weight; ER, estrogen receptor; FCDF, Fischer CDF; F344, Fischer 344; GD, gestational day; i.p, intraperitoneal; OF-1, Oncins France 1; PND, postnatal day; PPARγ, peroxisome proliferator-activated receptor gamma; pWAT, perigonadal adipose tissue; S-D, Sprague-Dawley. Significant doses are statistically significant changes compared with controls.
Animals were challenged with a high-fat diet or fructose.
The benchmark dose approach was used in this study.